WallStreetZenWallStreetZen

NASDAQ: VRCA
Verrica Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their VRCA stock forecasts and price targets.

Forecast return on equity

Is VRCA forecast to generate an efficient return?

Company
-59.43%
Industry
123.99%
Market
-49.26%
VRCA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VRCA forecast to generate an efficient return on assets?

Company
26.57%
Industry
47.19%
VRCA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VRCA earnings per share forecast

What is VRCA's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$3.00
Avg 2 year Forecast
-$2.40
Avg 3 year Forecast
-$0.20

VRCA revenue forecast

What is VRCA's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$25.6M+73.76%
Avg 2 year Forecast
$23.7M+61.18%
Avg 3 year Forecast
$55.8M+279.62%
VRCA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VRCA revenue growth forecast

How is VRCA forecast to perform vs Biotechnology companies and vs the US market?

Company
50.02%
Industry
78.34%
Market
10.8%
VRCA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VRCA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VRCA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VRCA$5.47N/AN/A
GUTS$1.02$6.00+488.24%Strong Buy
NRXP$2.64$29.25+1,007.95%Strong Buy
VTVT$16.00$36.00+125.00%Buy
MAIA$1.58N/AN/A
View Top Biotech Stocks

Verrica Pharmaceuticals Stock Forecast FAQ

What is VRCA's earnings growth forecast for 2025-2027?

(NASDAQ: VRCA) Verrica Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.32%.

Verrica Pharmaceuticals's earnings in 2025 is -$48,600,000.On average, 2 Wall Street analysts forecast VRCA's earnings for 2025 to be -$28,337,304, with the lowest VRCA earnings forecast at -$32,115,611, and the highest VRCA earnings forecast at -$24,558,997. On average, 1 Wall Street analyst forecast VRCA's earnings for 2026 to be -$22,669,843, with the lowest VRCA earnings forecast at -$22,669,843, and the highest VRCA earnings forecast at -$22,669,843.

In 2027, VRCA is forecast to generate -$1,889,154 in earnings, with the lowest earnings forecast at -$1,889,154 and the highest earnings forecast at -$1,889,154.

If you're new to stock investing, here's how to buy Verrica Pharmaceuticals stock.

What is VRCA's revenue growth forecast for 2025-2027?

(NASDAQ: VRCA) Verrica Pharmaceuticals's forecast annual revenue growth rate of 50.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.34%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.8%.

Verrica Pharmaceuticals's revenue in 2025 is $14,704,000.On average, 2 Wall Street analysts forecast VRCA's revenue for 2025 to be $241,339,372, with the lowest VRCA revenue forecast at $170,023,824, and the highest VRCA revenue forecast at $312,654,921. On average, 1 Wall Street analysts forecast VRCA's revenue for 2026 to be $223,864,702, with the lowest VRCA revenue forecast at $223,864,702, and the highest VRCA revenue forecast at $223,864,702.

In 2027, VRCA is forecast to generate $527,262,770 in revenue, with the lowest revenue forecast at $527,262,770 and the highest revenue forecast at $527,262,770.

What is VRCA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: VRCA) forecast ROA is 26.57%, which is lower than the forecast US Biotechnology industry average of 47.19%.

What is VRCA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: VRCA) Verrica Pharmaceuticals's current Earnings Per Share (EPS) is -$7.68. On average, analysts forecast that VRCA's EPS will be -$3.00 for 2025, with the lowest EPS forecast at -$3.40, and the highest EPS forecast at -$2.60. On average, analysts forecast that VRCA's EPS will be -$2.40 for 2026, with the lowest EPS forecast at -$2.40, and the highest EPS forecast at -$2.40. In 2027, VRCA's EPS is forecast to hit -$0.20 (min: -$0.20, max: -$0.20).

What is VRCA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: VRCA) forecast ROE is -59.43%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.